Table 1.

Modulators, CAS # identifiers, and expected targets for each.

Modulator	CAS #	Target
BIIB021	848695–25-0	HSP90 inhibitor
BSO	5072–26-4	Glutamate Cysteine Ligase inhibitor
CoCl2	7646–79-9	HIF1a/hypoxia inducer
DMPS	74–61-3	divalent cation chelator
Eliprodil	119431–25-3	NMDA Antagonist
GSK-1904529A	1089283–49-7	IGF-1R/IR inhibitor
KU0063794	938440–64-3	mTOR inhibitor
L-NAME	50903–99-6	NOS inhibitor
NAC	616–91-1	ROS scavenger
necrostatin 1	4311–88-0	RIP1K inhibitor
necrostatin 5	337349–54-9	RIP1K inhibitor
necrostatin 7	351062–08-3	necroptosis inhibitor
Nicotinamide	98–92-0	SIRT1/2/3/6 inhibitor
o-Phenanthroline	3248–05-3	Chelator of divalent cations
Pazopanib	444731–52-6	VEGFR1/2/3 inhibitor
Saquinavir	149845–06-7	HIV protease- and CYP3A4 inhibitor
SP-600125	129–56-6	JNK1, JNK2, JNK3 inhibitor
SRT1720	1001645–58-4	SIRT1 activator
TPEN	16858–02-9	divalent cation chelator
TW-37	877877–35-5	BCL2-binding inhibitor
WYE-354	1062169–56-5	mTOR inhibitor

Abbreviations: BSO, buthionine sulphoximine; DMPS, 2,3-dimercapto-1-propanesulfonic acid; GSH, reduced glutathione; L-NAME, NG-Nitroarginine Methyl Ester; L-NMMA, NG-Methyl-L-arginine acetate salt; NAC, N-acetyl-L-cysteine; PHE, o-Phenanthroline; and TPEN, (N,N,N’, N’-tetrakis(2-pyridylmethyl)-ethylenediamine; IGF1R, Insulin-like Growth Factor 1 Receptor; IR, Insulin Receptor; NOS, Nitric Oxide Synthase (−1, −2, and −3); A full list of the 70 modulators used in screenings is available in Supplementary Table S1.